Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 1
2005 3
2006 11
2007 4
2008 3
2009 3
2010 9
2011 5
2012 8
2013 8
2014 3
2015 15
2016 11
2017 9
2018 7
2019 11
2020 9
2021 5
2022 5
2023 4
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP. Yarom N, et al. Among authors: van poznak ch. J Clin Oncol. 2019 Sep 1;37(25):2270-2290. doi: 10.1200/JCO.19.01186. Epub 2019 Jul 22. J Clin Oncol. 2019. PMID: 31329513
Management of Male Breast Cancer: ASCO Guideline.
Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, Plichta JK, Ricker C, Roshal A, Ruddy KJ, Safer JD, Van Poznak C, Yung RL, Giordano SH. Hassett MJ, et al. Among authors: van poznak c. J Clin Oncol. 2020 Jun 1;38(16):1849-1863. doi: 10.1200/JCO.19.03120. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058842
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Tolaney SM, et al. Among authors: van poznak c. J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34077270 Clinical Trial.
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH. Eisen A, et al. Among authors: van poznak ch. J Clin Oncol. 2022 Mar 1;40(7):787-800. doi: 10.1200/JCO.21.02647. Epub 2022 Jan 18. J Clin Oncol. 2022. PMID: 35041467
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.
Hadji P, Aapro M, Al-Dagri N, Alokail M, Biver E, Body JJ, Brandi ML, Brown J, Confavreux C, Cortet B, Drake M, Ebeling P, Eriksen EF, Fuleihan GE, Guise TA, Harvey NC, Kurth A, Langdahl B, Lems W, Matijevic R, McCloskey E, Nappi R, Palacios S, Pfeiler G, Reginster JY, Rizzoli R, Santini D, Tuzun S, Poznak CV, Villiers T, Zillikens MC, Coleman R. Hadji P, et al. Among authors: poznak cv. J Bone Oncol. 2025 Jun 11;53:100694. doi: 10.1016/j.jbo.2025.100694. eCollection 2025 Aug. J Bone Oncol. 2025. PMID: 40726588 Free PMC article. Review.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM; Consortium of the TBCRC Translational Investigators; TBCRC Translational Investigators. Tarantino P, et al. Among authors: van poznak c. J Clin Oncol. 2024 Nov;42(31):3652-3665. doi: 10.1200/JCO.23.02170. Epub 2024 Jun 27. J Clin Oncol. 2024. PMID: 38935923 Free PMC article. Clinical Trial.
Pharmacologic management of metastatic bone disease.
Schwartz E, Reichert Z, Van Poznak C. Schwartz E, et al. Among authors: van poznak c. Bone. 2022 May;158:115735. doi: 10.1016/j.bone.2020.115735. Epub 2020 Nov 7. Bone. 2022. PMID: 33171313 Review.
131 results